DANIELLE BARBARO: Open Payments
NPI 1194224493 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$195 in 10 payments from 7 companies in 2025. Trend: 2023 $173 · 2024 $0 · 2025 $195
Food & beverage: $195
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Lilly USA, LLC | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Novo Nordisk Inc | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $18 |
Products named: BREZTRI, ABILIFY MAINTENA, ZEPBOUND, RECORLEV, CAPLYTA, Ozempic, TRELEGY ELLIPTA.
Industry payments across AZ — which companies pay providers there.
